|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
Bromopyruvate Revealed [In the Pipeline]
|
|
|
|
|
|
What
this says to me is that while GAPDH inhibition might well be a
metabolic target for some tumor types, bromopyruvic acid is a pretty
crude tool to accomplish this. You would worry that a molecule this
small and this reactive would be accompanied by severe toxicity, and
that’s just what you get.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Side Effects From Certain Immunotherapies May Be Higher Than Initially Reported [ASCO]
|
|
|
|
|
|
An
analysis of nearly 2,800 people with non-small cell lung cancer (NSCLC)
who received the immune checkpoint inhibitors nivolumab (Opdivo),
pembrolizumab (Keytruda), or atezolizumab (Tecentriq) found that
unexpected medical problems, known as adverse events, may be more common
than reported in the initial trials that led to the approval of these
therapies.
|
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.9.4 ENA
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
At 24, Two Entrepreneurs Took On Cancer. At 32, They’re Worth Hundreds Of Millions [Forbes]
|
|
|
|
|
|
Flatiron’s
solution is to own the right to use data from an electronic medical
record used by nearly 280 medical practices for 2 million patients. It
pays 1,000 contractors to read the text notes doctors write about their
patients and turn the notes into data on what medicines patients take,
how well they work, and what happens next. This can be turned into a
larger data set that measures how well medicines are actually working, a
potential that has Flatiron collaborating with all the largest makers
of cancer drugs.
|
|
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
Did IBM overhype Watson Health's AI promise? [Computer World]
|
|
|
|
|
|
The
Cancer Center and IBM Watson ceased active development in 2015. And IBM
ended support for the OEA Pilot System and for the OEA Demo System
effective Sept. 1, 2016. The system is not in clinical use and has not
been piloted outside of M.D. Anderson, according to the the audit.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Jury clears J&J of liability in California talc cancer case [Reuters]
|
|
|
|
|
|
The
jury in Humboldt County Superior Court in Eureka, California rejected
claims by Carla Allen who said that her mesothelioma, a tissue cancer
closely linked to asbestos exposure, was caused by the company’s talc
products, including Johnson’s Baby Powder. J&J denies the
allegations, saying decades of scientific testing and regulatory
approvals have shown its talc to be safe and asbestos-free.
|
|
|
|
|
|